Endo Sees Regulatory Setting For Opana ER As "A Moving Target"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The “complete response” letter for the crush-resistant formulation of Endo Pharmaceuticals’ chronic pain drug Opana ER (oxymorphone) is not surprising, given that FDA has yet to settle on a risk management approach for extended-release opioids.